STOCK TITAN

Inspiremd Stock Price, News & Analysis

NSPR NASDAQ

Company Description

Overview of InspireMD Inc.

InspireMD Inc. is a United States based medical device company that specializes in the development and commercialization of advanced stent platforms for the treatment of complex vascular and coronary diseases. With its innovative MicroNet stent technology integrated into its devices, InspireMD addresses the challenges of carotid artery stenosis and stroke prevention, providing acute and durable, stroke-free outcomes. The company's operations are underpinned by rigorous clinical evaluation, robust research methodologies, and participation in influential interventional conferences that underscore its commitment to clinical excellence and data-driven practice.

Core Business and Technology

At its core, InspireMD leverages a proprietary design that combines a self-expandable nitinol stent with a MicroNet mesh to offer comprehensive embolic protection during carotid interventions. This dual-component system is engineered to optimize acute performance while also ensuring sustained long-term efficacy in stroke prevention. The integration of advanced biomaterials with innovative stenting methods positions InspireMD as a noteworthy player in the realm of vascular interventional devices.

Clinical Evidence and Global Reach

InspireMD has built its reputation on a foundation of strong clinical evidence, with multiple clinical trials across the United States and Europe validating the safety and efficacy of its devices. The products have been evaluated in pivotal studies, where key endpoints such as the reduction of major adverse events have been meticulously documented. The company's involvement in international clinical trials and its presence at globally recognized congresses highlight its commitment to establishing credibility and continuous improvement in medical practice.

Market Position and Competitive Landscape

Within the competitive landscape of medical devices, InspireMD distinguishes itself through its specialized focus on carotid stenting systems. The company has cultivated a niche by addressing unmet needs in the management of carotid artery disease through the integration of state-of-the-art technology with clinical validation. Its expansive network, spanning markets in Europe, the United States, and other key regions, further reinforces its status as a globally aware and clinically driven entity.

Operational Model and Regulatory Focus

The business model of InspireMD revolves around direct sales of its innovative stent systems to healthcare providers, bolstered by ongoing clinical trials that support regulatory compliance and product improvement. By streamlining manufacturing and enhancing operational capabilities in strategic regions, such as its new headquarters in the U.S., the company strengthens its commercial infrastructure in anticipation of broad-based market adoption. Regulatory milestones, including Pre-Market Approval (PMA) submissions and inclusion in major clinical trials, underscore the adept handling of compliance and product safety standards.

Commitment to Clinical Excellence and Innovation

InspireMD remains committed to advancing the field of carotid interventions by continuously refining its technology based on rigorous clinical study outcomes. The company leverages its proprietary technology to offer sustainable solutions for stroke prevention, ensuring that both the short-term procedural success and long-term patient outcomes are optimized for safety and efficacy. This constant drive for innovation not only enhances patient care but also builds long-term trust with healthcare providers and regulators.

Summary

  • Innovative Technology: Utilizes proprietary MicroNet stent technology for enhanced embolic protection.
  • Rigorous Clinical Validation: Backed by multiple clinical trials across key international markets.
  • Global Reach: Maintains a presence in major markets with a focus on regulatory excellence and clinical performance.
  • Focused Operations: Streamlines its business model around direct sales and a robust global operational framework.

This detailed exploration of InspireMD Inc. provides an informative and comprehensive view of its strategic positioning in the medical device industry, delivering clear insights for investors and industry stakeholders.

Stock Performance

$2.50
+1.90%
+0.05
Last updated: April 30, 2025 at 12:26
-2.95 %
Performance 1 year
$79.7M
Market Cap
30.6M
Shares outstanding

SEC Filings

No SEC filings available for Inspiremd.

Financial Highlights

$7,009,000
Revenue (TTM)
-$32,005,000
Net Income (TTM)
-$0.76
Diluted EPS (TTM)
-$21,868,000
Operating Cash Flow
-456.63%
Net Profit Margin
-478.00%
Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the current stock price of Inspiremd (NSPR)?

The current stock price of Inspiremd (NSPR) is $2.4534 as of April 29, 2025.

What is the market cap of Inspiremd (NSPR)?

The market cap of Inspiremd (NSPR) is approximately 79.7M.

What is the revenue (TTM) of Inspiremd (NSPR) stock?

The trailing twelve months (TTM) revenue of Inspiremd (NSPR) is $7,009,000.

What is the net income of Inspiremd (NSPR)?

The trailing twelve months (TTM) net income of Inspiremd (NSPR) is -$32,005,000.

What is the earnings per share (EPS) of Inspiremd (NSPR)?

The diluted earnings per share (EPS) of Inspiremd (NSPR) is -$0.76 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Inspiremd (NSPR)?

The operating cash flow of Inspiremd (NSPR) is -$21,868,000.

What is the profit margin of Inspiremd (NSPR)?

The net profit margin of Inspiremd (NSPR) is -456.63%.

What is the operating margin of Inspiremd (NSPR)?

The operating profit margin of Inspiremd (NSPR) is -478.00%.

What is the gross margin of Inspiremd (NSPR)?

The gross profit margin of Inspiremd (NSPR) is 21.49%.

What is the current ratio of Inspiremd (NSPR)?

The current ratio of Inspiremd (NSPR) is 5.28, indicating the company's ability to pay short-term obligations.

What is the gross profit of Inspiremd (NSPR)?

The gross profit of Inspiremd (NSPR) is $1,506,000 on a trailing twelve months (TTM) basis.

What is the operating income of Inspiremd (NSPR)?

The operating income of Inspiremd (NSPR) is -$33,503,000.

What is the core focus of InspireMD Inc.?

InspireMD Inc. specializes in developing and commercializing advanced stent systems for the treatment of complex vascular and coronary diseases, with a particular focus on carotid stenting for stroke prevention.

How does the MicroNet stent technology work?

The MicroNet stent technology integrates a self-expandable nitinol stent with an innovative mesh structure designed to reduce embolic events during carotid interventions, thereby enhancing both immediate and long-term patient outcomes.

In which markets does InspireMD operate?

InspireMD operates across multiple international markets, including its home base in the United States, as well as in Europe and other global regions, ensuring a widespread clinical impact and robust market presence.

What clinical evidence supports InspireMD's products?

The company has conducted and participated in extensive clinical trials that validate the safety and efficacy of its stent systems, with data presented at influential clinical conferences, supporting rigorous clinical endpoints.

How does InspireMD differentiate itself from its competitors?

InspireMD differentiates itself through its proprietary MicroNet technology, a strong focus on clinical validation, and its strategic operational model that targets specific needs in carotid interventions and stroke prevention.

What steps has InspireMD taken towards regulatory approval?

The company has submitted key applications, including Premarket Approval (PMA) submissions to the FDA, and has been involved in multiple clinical trials that align with regulatory standards to support the safety and efficacy of its devices.

How does InspireMD generate revenue?

InspireMD primarily generates revenue through the sales of its innovative stent systems, supported by clinical validations and an expanding network of healthcare providers across its operating markets.

What advantages does InspireMD’s technology offer in stroke prevention?

By combining a self-expandable nitinol stent with an advanced MicroNet mesh, InspireMD’s technology provides enhanced embolic protection, lowering the risk of stroke and improving both short-term procedural and long-term patient outcomes.